Home › Companies › ONCY

Pipeline (3 active programs)

Discontinued (1)

• pelareorep — Pancreatic Ductal Adenocarcinoma · strategic deprioritization to focus on SCAC and CRC registrational programs; enrollment stopped at ~20 patients per arm

Capital (as filed)

Cash

$4.1M cash and cash equivalents · Jun 30, 2026 (10-Q)

Operating cash flow

−$8.1M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)

As stated in coverage

$4.1M cash per the deep dive of Sep 16, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

• 2026-10-28 UPDATE: Oncolytics Biotech (ONCY) - The Draft Footnote 🔒 Paid
• 2026-09-17 Oncolytics Biotech (ONCY) - Scientific Deep Dive for Pelareorep and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Oncolytics Biotech, oldest first — the full history, never a selection. How calls are scored: the track record.

1. 2026-09-17 Avoid Oncolytics Biotech (ONCY) - Scientific Deep Dive for Pelareorep and Pipeline Products Twenty-eight years of pharmacodynamic receipts have not produced a randomized benefit, the one randomized colorectal precedent was negative on PFS, and the trial is funded by an ATM drip with a reverse split and Nasdaq deadline looming — revisit only when REO 033 reports randomized Part A data with both arms' denominators and a partner funds Part B.
2. 2026-10-28 Avoid UPDATE: Oncolytics Biotech (ONCY) - The Draft Footnote GOBLET final data added nothing new — DOR is a restatement, response rate and denominator are absent, the anal cancer program remains unfunded, dilution per dollar has roughly doubled, and only randomized REO 033 Part A data with full denominators and a partner funding registration can change the thesis.

• Avoid call · opened Sep 17, 2026 at $0.770 · -42.9% vs XBI -3.8% (Nov 6, 2026)

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

• 2026-08-12 10-Q in filings ↓

  • “Accessed April 28, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer 4 Bennouna J. Lancet Oncol (14):29-37, 2023 21 During the second quarter of 2026, we continued with site initiation and expect that approximately half of the planned clinical sites will be activated during the third quarter of 2026.”

    matched to REO 033 · topline data · read as third quarter of 2026 / matched to REO 033 Part B · trial initiation · read as third quarter of 2026

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (39)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 28, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

• Nov 4, 2026ReleaseTranslational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
• Nov 4, 20268-KCurrent report: other events · EX-99.1
• Oct 27, 2026ReleaseOncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers→ BD updateSummary on the 8-K
• Oct 27, 20268-KCurrent report: other events · EX-99.1→ BD updateGOBLET Cohort 4's long-awaited final durability data just landed — ~15-month median DOR, all responders alive past 12 months — but the market isn't buying it, and a buried footnote reveals the efficacy figures come from "internal calculations for this draft," not a peer-reviewed dataset.
• Oct 20, 2026ReleaseOncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
• Oct 20, 20268-KCurrent report: other events · EX-99.1
• Oct 14, 2026ReleaseOncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
• Oct 14, 20268-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → ONCY pipeline
• Oct 13, 20268-KCurrent report: other events · EX-99.1
• Oct 12, 2026ReleaseOncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
• Oct 6, 2026DEFA14AProxy soliciting material
• Oct 6, 2026DEF 14AProxy statement
• Sep 29, 2026ReleaseOncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
• Sep 29, 20268-KCurrent report: other events · EX-99.1
• Sep 28, 2026ReleaseOncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
• Sep 28, 20268-KCurrent report: other events · EX-99.1
• Sep 10, 20268-KCurrent report: other events · EX-99.1
• Aug 18, 20268-KCurrent report: other events · EX-99.1
• Aug 12, 202610-QQuarterly report
• Jul 24, 20268-KCurrent report: listing notice
• Jul 20, 20268-KCurrent report: other events · EX-99.1
• Jul 13, 20268-KCurrent report: other events · EX-99.1
• Jul 8, 20268-KCurrent report: auditor change
• Jun 16, 20268-KCurrent report: other events · EX-99.1
• Jun 2, 20268-KCurrent report: officer / director change, other events · EX-99.1
• Jun 1, 20268-KCurrent report: other events · EX-99.1
• May 22, 20268-KCurrent report: other events · EX-99.1
• May 14, 202610-QQuarterly report
• May 4, 20268-KCurrent report: other events · EX-99.1
• Apr 27, 20268-KCurrent report: other events · EX-99.1
• Apr 6, 20268-KCurrent report: other events · EX-99.1
• Apr 6, 20268-KCurrent report: other events
• Apr 6, 2026424B5Prospectus supplement (offering)
• Apr 1, 2026S-3Shelf registration
• Apr 1, 20268-KCurrent report: material agreement, holder rights modified, officer / director change · EX-99.2 EXHIBIT 99.2
• Mar 30, 202610-KAnnual report
• Mar 20, 20268-KCurrent report: holder rights modified, charter / bylaws / fiscal year
• Mar 19, 20268-KCurrent report: other events · EX-99.1
• Mar 2, 20268-KCurrent report: other events · EX-99.1